LFCR Key Statistics, Chart & Performance
The current stock price of LFCR is 8.47 USD. In the past month the price increased by 11.45%. In the past year, price increased by 16.99%.
LFCR Latest News, Press Relases and Analysis
LFCR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.11 | 211.36B | ||
| DHR | DANAHER CORP | 28.88 | 157.25B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 172.38 | 52.38B | ||
| A | AGILENT TECHNOLOGIES INC | 24.49 | 38.74B | ||
| IQV | IQVIA HOLDINGS INC | 19.04 | 37.71B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.09 | 28.29B | ||
| WAT | WATERS CORP | 29.69 | 22.45B | ||
| ILMN | ILLUMINA INC | 29.72 | 19.80B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.07 | 19.36B | ||
| MEDP | MEDPACE HOLDINGS INC | 38.96 | 15.69B | ||
| TEM | TEMPUS AI INC | N/A | 11.50B | ||
| RVTY | REVVITY INC | 20.2 | 10.97B |
Related stock screener links
About LFCR
Company Profile
Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. The company is headquartered in Chaska, Minnesota and currently employs 406 full-time employees. The firm designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The firm offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The firm uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
Company Info
LIFECORE BIOMEDICAL INC
3515 Lyman Boulevard
Chaska MINNESOTA US
Employees: 406
Phone: 19523684300
LIFECORE BIOMEDICAL INC / LFCR FAQ
What does LFCR do?
Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. The company is headquartered in Chaska, Minnesota and currently employs 406 full-time employees. The firm designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The firm offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The firm uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
What is the stock price of LIFECORE BIOMEDICAL INC today?
The current stock price of LFCR is 8.47 USD. The price increased by 9.86% in the last trading session.
What is the dividend status of LIFECORE BIOMEDICAL INC?
LFCR does not pay a dividend.
How is the ChartMill rating for LIFECORE BIOMEDICAL INC?
LFCR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of LIFECORE BIOMEDICAL INC (LFCR)?
LIFECORE BIOMEDICAL INC (LFCR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.07).
Can you provide the market cap for LIFECORE BIOMEDICAL INC?
LIFECORE BIOMEDICAL INC (LFCR) has a market capitalization of 317.37M USD. This makes LFCR a Small Cap stock.
What is the Short Interest ratio of LIFECORE BIOMEDICAL INC (LFCR) stock?
The outstanding short interest for LIFECORE BIOMEDICAL INC (LFCR) is 7.38% of its float.
LFCR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to LFCR. When comparing the yearly performance of all stocks, LFCR is one of the better performing stocks in the market, outperforming 77.48% of all stocks.
LFCR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LFCR. Both the profitability and financial health of LFCR have multiple concerns.
LFCR Financial Highlights
Over the last trailing twelve months LFCR reported a non-GAAP Earnings per Share(EPS) of -1.07. The EPS decreased by -2114.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.6% | ||
| ROE | -106.13% | ||
| Debt/Equity | 3.67 |
LFCR Forecast & Estimates
11 analysts have analysed LFCR and the average price target is 8.93 USD. This implies a price increase of 5.37% is expected in the next year compared to the current price of 8.47.
For the next year, analysts expect an EPS growth of 36.35% and a revenue growth 1.62% for LFCR